Zealand Pharma A/S (ZEAL) Publishes Phase 2 Petrelintide Data; To Present at EASD

Zealand Pharma A/S said Phase 2 ZUPREME-1 results for petrelintide were published in The Lancet Diabetes & Endocrinology and will be presented at EASD 2026 on Sept. 30 at 3:30pm CEST.Material DetailsContext by AI AnalystThis is mid-cycle validation for Zealand’s obesity pipeline, moving petrelintid…